MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Inclusion Criteria:

Diagnosed with malignant melanoma
Measurable unresectable Stage III or IV melanoma
HLA-A*0201 positive
Previous treatment with & failure/relapse/inability to tolerate IL-2, dacarbazine and/or temozolomide
At least 4 weeks since prior treatment
Negative pregnancy
Life expectancy greater than 4 months
Eastern Cooperative Oncology Group (ECOG) performance of 0 or 1
Required lab values
Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) negative

Exclusion Criteria:

Prior malignancies which the patient has not been disease free for over 5 years, except treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or any other cancer
Ocular melanoma
Active, untreated central nervous system (CNS) metastasis
Prior treatment with MDX-010 (anti-CTLA4) antibody
Prior treatment with any cancer therapeutic vaccine
Active autoimmune disease or history of autoimmune disease
Pregnancy or nursing
Hypersensitivity to Incomplete Freund's Adjuvant (IFA) (Montanide ISA-51)
Underlying medical conditions deemed hazardous if treated with study drug
Concomitant therapy with anti-melanoma drugs, chemotherapies, other investigational therapies, chronic use of systemic corticosteroids
Unable to provide informed consent